180 related articles for article (PubMed ID: 21665504)
21. Thirty-two month follow-up of successful treatment of choroidal neovascularization from angioid streaks with intravitreal bevacizumab.
Kovach JL; Schwartz SG; Hickey M; Puliafito CA
Ophthalmic Surg Lasers Imaging; 2009; 40(1):77-9. PubMed ID: 19205505
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of bevacizumab for posttraumatic choroidal neovascularization.
Joo K; Um T; Park SJ; Cho JH; Ahn J; Kim JT; Lee JY; Park KH; Woo SJ
Acta Ophthalmol; 2019 Mar; 97(2):e324-e326. PubMed ID: 30414255
[No Abstract] [Full Text] [Related]
23. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.
Tewari A; Dhalla MS; Apte RS
Retina; 2006; 26(9):1093-4. PubMed ID: 17151505
[No Abstract] [Full Text] [Related]
24. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum.
Bhatnagar P; Freund KB; Spaide RF; Klancnik JM; Cooney MJ; Ho I; Fine HF; Yannuzzi LA
Retina; 2007 Sep; 27(7):897-902. PubMed ID: 17891014
[TBL] [Abstract][Full Text] [Related]
26. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab injection in a 14-year-old Vogt-Koyanagi-Harada patient with choroidal neovascular membrane.
Raffa L; Bawazeer A
Can J Ophthalmol; 2009 Oct; 44(5):615-6. PubMed ID: 19789612
[No Abstract] [Full Text] [Related]
31. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab.
Almony A; Mansouri A; Shah GK; Blinder KJ
Can J Ophthalmol; 2011 Apr; 46(2):182-5. PubMed ID: 21708088
[TBL] [Abstract][Full Text] [Related]
32. [Intravitreal bevacizumab treatment for choroidal neovascularization in Best's disease].
Perol J; Wolff B; Sahel JA; Le Mer Y
J Fr Ophtalmol; 2011 May; 34(5):281-6. PubMed ID: 21507509
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks.
Rinaldi M; Dell'Omo R; Romano MR; Chiosi F; Cipollone U; Costagliola C
Arch Ophthalmol; 2007 Oct; 125(10):1422-3. PubMed ID: 17923555
[No Abstract] [Full Text] [Related]
34. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.
Mandal S; Garg S; Venkatesh P; Mithal C; Vohra R; Mehrotra A
Arch Ophthalmol; 2007 Nov; 125(11):1487-92. PubMed ID: 17998509
[TBL] [Abstract][Full Text] [Related]
36. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
37. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis.
Fine HF; Zhitomirsky I; Freund KB; Barile GR; Shirkey BL; Samson CM; Yannuzzi LA
Retina; 2009 Jan; 29(1):8-12. PubMed ID: 18784620
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab for choroidal neovascularization related to inflammatory diseases.
Kramer M; Axer-Siegel R; Jaouni T; Reich E; Hemo I; Priel E; Averbukh E; Ehrlich R; Chowers I; Weinberger D; Amer R
Retina; 2010 Jun; 30(6):938-44. PubMed ID: 20168273
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
